Abstract
Vemurafenib and dabrafenib selectively inhibit the v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) kinase, resulting in high response rates and increased survival in melanoma. Approximately 22% of individuals treated with vemurafenib develop cutaneous squamous cell carcinoma (cSCC) during therapy. The prevailing explanation for this is drug-induced paradoxical ERK activation, resulting in hyperproliferation. Here we show an unexpected and novel effect of vemurafenib/PLX4720 in suppressing apoptosis through the inhibition of multiple off-target kinases upstream of c-Jun N-terminal kinase (JNK), principally ZAK. JNK signaling is suppressed in multiple contexts, including in cSCC of vemurafenib-treated patients, as well as in mice. Expression of a mutant ZAK that cannot be inhibited reverses the suppression of JNK activation and apoptosis. Our results implicate suppression of JNK-dependent apoptosis as a significant, independent mechanism that cooperates with paradoxical ERK activation to induce cSCC, suggesting broad implications for understanding toxicities associated with BRAF inhibitors and for their use in combination therapies.
Original language | English (US) |
---|---|
Article number | e00969 |
Journal | eLife |
Volume | 2013 |
Issue number | 2 |
DOIs | |
State | Published - Nov 5 2013 |
ASJC Scopus subject areas
- General Neuroscience
- General Immunology and Microbiology
- General Biochemistry, Genetics and Molecular Biology
MD Anderson CCSG core facilities
- Advanced Technology Genomics Core
- Flow Cytometry and Cellular Imaging Facility
- Research Animal Support Facility